Evidence map›Paper›PMID 41340866›Full record

ArticleGynecologic oncology reports2025

Shariska P Harrington, Jacqueline Romani, Aminah Jatoi, S John Weroha, Andrea Mariani, William A Cliby, Jamie N Bakkum-Gamez, Dineo Khabele, Alexandre Gaspar-Maia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shariska P HarringtonDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA.
Jacqueline RomaniDepartment of Lab Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA.
Aminah JatoiDepartment of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
S John WerohaDepartment of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Andrea MarianiDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA.
William A ClibyDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA.
Jamie N Bakkum-GamezDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA.
Dineo KhabeleDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology and Siteman Cancer Center, St. Louis, MO, USA.
Alexandre Gaspar-MaiaDepartment of Lab Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA.

Funding

Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · MAYO CLINIC ROCHESTER · 2001 to 2025
$3.0M
NCI NIH HHS K12 CA090628
6 · The paper itself

Abstract

Objective: Copy number high (CNH) endometrial cancer (EC) is an aggressive molecular subgroup characterized by TP53 mutations and relative chemoresistance. CNH EC with cyclin E1 gene ( Methods: Copy number variation and molecular subtype classification were extracted from The Cancer Genome Atlas for 529 ECs. Amplification status was determined for Results: Of all ECs profiled, Conclusions: ECs with

Indexed as

Copy number highEndometrial cancerMECOMPoor prognosis

Identifiers

PMID41340866
PMCPMC12670447

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.